HRP20231277T1 - Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije - Google Patents
Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije Download PDFInfo
- Publication number
- HRP20231277T1 HRP20231277T1 HRP20231277TT HRP20231277T HRP20231277T1 HR P20231277 T1 HRP20231277 T1 HR P20231277T1 HR P20231277T T HRP20231277T T HR P20231277TT HR P20231277 T HRP20231277 T HR P20231277T HR P20231277 T1 HRP20231277 T1 HR P20231277T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- use according
- phe
- lys
- arg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
1. Peptid predstavljen formulom D-Arg-2'6'-Dmt-Lys-Phe-NH2 ili Phe-D-Arg-Phe-Lys-NH2, za liječenje ili prevenciju oftalmološkog stanja, pri čemu je oftalmološko stanje makularna degeneracija.
2. Peptid za upotrebu sukladno patentnom zahtjevu 1, naznačen time da je peptid D-Arg-2’6’-Dmt-Lys-Phe-NH2.
3. Peptid za upotrebu sukladno patentnom zahtjevu 1, naznačen time da je peptid Phe-D-Arg-Phe-Lys-NH2.
4. Peptid za upotrebu sukladno patentnom zahtjevu 1, naznačen time da je subjekt čovjek.
5. Peptid za upotrebu sukladno patentnom zahtjevu 1, naznačen time da je peptid formuliran za intraokularnu primjenu, iontoforetski, oralno, lokalno, sistemski, intravenozno, subkutano ili intramuskularno.
6. Peptid za upotrebu sukladno patentnom zahtjevu 1, naznačen time da je peptid formuliran za primjenu s drugim aktivnim sredstvom.
7. Peptid za upotrebu sukladno patentnom zahtjevu 6, naznačen time da je drugo aktivno sredstvo odabrano iz skupine koju čine: antioksidans, metalni komplekser, protuupalni lijek, antibiotik i antihistaminik.
8. Peptid za upotrebu sukladno patentnom zahtjevu 7, naznačen time da je antioksidans vitamin A, vitamin C, vitamin E, likopen, selen, α-lipoična kiselina, koenzim Q, glutation ili karotenoid.
9. Peptid za upotrebu sukladno patentnom zahtjevu 6, gdje je drugo aktivno sredstvo odabrano iz skupine koju čine: aceklidin, acetazolamid, anekortav, apraklonidin, atropin, azapentacen, azelastin, bacitracin, befunolol, betametazon, betaksolol, bimatoprost, brimonidin, brinzolamid, karbahol, karteolol, celekoksib, kloramfenikol, klortetraciklin, ciprofloksacin, kromoglikat, kromolin, ciklopentolat, ciklosporin, dapiprazol, demekarij, deksametazon, diklofenak, diklorfenamid, dipivefrin, dorzolamid, ehotiofat, emedastin, epinastin, epinefrin, eritromicin, etokzolamid, eukatropin, fludrokortizon, fluorometolon, flurbiprofen, fomivirsen, framicetin, ganciklovir, gatifloksacin, gentamicin, homatropin, hidrokortizon, idoksuridin, indometacin, izoflurofat, ketorolak, ketotifen, latanoprost, levobetaksolol, levobunolol, levokabastin, levofloksacin, lodoksamid, loteprednol, medrizon, metazolamid, metipranolol, moksifloksacin, nafazolin, natamicin, nedokromil, neomicin, norfloksacin, ofloksacin, olopatadin, oksimetazolin, pemirolast, pegaptanib, fenilefrin, fizostigmin, pilokarpin, pindolol, pirenoksin, polimiksin B, prednizolon, proparakain, ranibizumab, rimeksolon, skopolamin, sezolamid, skvalamin, sulfacetamid, suprofen, tetrakain, tetraciklin, tetrahidrozolin, tetrizolin, timolol, tobramicin, travoprost, triamcinulon, trifluorometazolamid, trifluridin, trimetoprim, tropikamid, unoproston, vidarbin, ksilometazolin, njihove farmaceutski prihvatljive soli i njihove kombinacije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23644009P | 2009-08-24 | 2009-08-24 | |
| US23774509P | 2009-08-28 | 2009-08-28 | |
| US34847010P | 2010-05-26 | 2010-05-26 | |
| EP20156769.0A EP3708178B1 (en) | 2009-08-24 | 2010-08-23 | Peptide for use in preventing or treating macular degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231277T1 true HRP20231277T1 (hr) | 2024-02-02 |
Family
ID=43628336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231277TT HRP20231277T1 (hr) | 2009-08-24 | 2010-08-23 | Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US8470784B2 (hr) |
| EP (17) | EP3338788A1 (hr) |
| JP (7) | JP6120399B2 (hr) |
| CN (3) | CN105056206A (hr) |
| CA (1) | CA2772094C (hr) |
| DK (2) | DK2470191T3 (hr) |
| ES (2) | ES2964555T3 (hr) |
| FI (1) | FI3708178T3 (hr) |
| HK (4) | HK1204958A1 (hr) |
| HR (1) | HRP20231277T1 (hr) |
| HU (1) | HUE064800T2 (hr) |
| LT (1) | LT3708178T (hr) |
| PL (2) | PL3708178T3 (hr) |
| PT (2) | PT3708178T (hr) |
| SI (2) | SI3708178T1 (hr) |
| SM (1) | SMT202300433T1 (hr) |
| WO (1) | WO2011025734A1 (hr) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8698751B2 (en) | 2010-10-01 | 2014-04-15 | Z124 | Gravity drop rules and keyboard display on a multiple screen device |
| EP4541320A3 (en) | 2008-09-29 | 2025-07-09 | Edwards Lifesciences CardiAQ LLC | Heart valve |
| WO2010040009A1 (en) | 2008-10-01 | 2010-04-08 | Cardiaq Valve Technologies, Inc. | Delivery system for vascular implant |
| JP2012523894A (ja) | 2009-04-15 | 2012-10-11 | カルディアック バルブ テクノロジーズ，インコーポレーテッド | 血管インプラント及びその配設システム |
| EP3338788A1 (en) | 2009-08-24 | 2018-06-27 | Stealth Peptides International, Inc. | Methods and copositions for preventing or treating opthalmic conditions |
| WO2011116007A1 (en) | 2010-03-15 | 2011-09-22 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP2563359A1 (en) * | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
| SG187770A1 (en) | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
| CN109705192A (zh) * | 2011-03-24 | 2019-05-03 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
| US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
| US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
| CN102327600A (zh) * | 2011-09-14 | 2012-01-25 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 用于预防和治疗辐射损伤的rx31肽 |
| US8842057B2 (en) | 2011-09-27 | 2014-09-23 | Z124 | Detail on triggers: transitional states |
| CA2858550A1 (en) * | 2011-12-09 | 2013-06-13 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| WO2013126597A1 (en) * | 2012-02-22 | 2013-08-29 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| CN107320712A (zh) * | 2012-03-30 | 2017-11-07 | 康德生物医疗技术公司 | 用于预防和治疗神经病的方法和组合物 |
| US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
| HK1210962A1 (en) * | 2012-08-02 | 2016-05-13 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
| JP6284341B2 (ja) * | 2012-10-24 | 2018-02-28 | 国立大学法人東京農工大学 | 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| CN110339339A (zh) * | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| CN105407906A (zh) * | 2013-03-01 | 2016-03-16 | 康德生物医疗技术公司 | 预防或治疗巴斯综合征的方法和组合物 |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US10583002B2 (en) | 2013-03-11 | 2020-03-10 | Neovasc Tiara Inc. | Prosthetic valve with anti-pivoting mechanism |
| US9681951B2 (en) | 2013-03-14 | 2017-06-20 | Edwards Lifesciences Cardiaq Llc | Prosthesis with outer skirt and anchors |
| US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
| CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| CA2919992C (en) * | 2013-08-01 | 2022-08-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating leber's hereditary optic neuropathy |
| CA2920735A1 (en) * | 2013-08-12 | 2015-02-19 | Stealth Biotherapeutics Corp | Combination therapy for the treatment of ischemia-reperfusion injury |
| JP2016539098A (ja) * | 2013-10-25 | 2016-12-15 | チルドレンズ メディカル センター コーポレーション | 網膜の血管障害を治療又は予防する方法 |
| CA2932408A1 (en) * | 2013-12-02 | 2015-06-11 | Stealth Biotherapeutics Corp | Compositions and methods for treating vitiligo |
| CA2936146A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating dominant optic atrophy |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| AU2015243261B2 (en) | 2014-04-10 | 2020-06-25 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of ocular diseases and disorders |
| US20170182117A1 (en) * | 2014-05-28 | 2017-06-29 | Stealth Biotherapeutics Corp | Therapeutic compositions including therapeutic small molecules and uses thereof |
| EP3233174B1 (en) * | 2014-12-19 | 2021-03-31 | Kemin Industries, Inc. | Intraocular delivery of bioactive molecules using iontophoresis |
| EP3397271B1 (en) | 2015-12-30 | 2021-11-03 | Marshall University Research Corporation | Compositions and methods for treating retinopathy |
| JP7038675B2 (ja) | 2016-03-11 | 2022-03-18 | ステルス バイオセラピューティクス インコーポレイテッド | 結晶塩形態 |
| CA3019178A1 (en) * | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| EP3606938A1 (en) | 2017-04-05 | 2020-02-12 | Stealth BioTherapeutics Corp | Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2 |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| JP7006990B2 (ja) | 2017-11-17 | 2022-02-10 | セリックス バイオ プライヴェート リミテッド | 眼障害の処置のための組成物及び方法 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| PL424452A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| WO2019213358A1 (en) * | 2018-05-03 | 2019-11-07 | Alimera Sciences, Inc. | Methods of treating retinal diseases |
| US20210330735A1 (en) * | 2018-07-16 | 2021-10-28 | Stealth Biotherapeutics Corp | Compositions and methods for the treatment of traumatic optic neuropathy |
| AU2019343188A1 (en) * | 2018-09-21 | 2021-05-20 | Aufbau Medical Innovations Limited | Compositions and methods for glaucoma |
| JP2022516796A (ja) * | 2019-01-12 | 2022-03-02 | セリックス バイオ プライヴェート リミテッド | 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 |
| JP2020174859A (ja) * | 2019-04-17 | 2020-10-29 | 学校法人日本医科大学 | 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法 |
| WO2020214990A1 (en) * | 2019-04-17 | 2020-10-22 | Ascidian Therapeutics, Inc. | Abca4 cell line and methods of use |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| EP4548973A3 (en) * | 2019-05-28 | 2025-07-23 | Elgan Pharma Ltd. | Compositions and methods for treating retinopathy |
| CN115996742A (zh) * | 2020-03-25 | 2023-04-21 | 奥夫博医疗创新有限公司 | 用于青光眼的方法和药剂 |
| JP7171971B1 (ja) * | 2020-12-24 | 2022-11-15 | 参天製薬株式会社 | エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 |
| WO2023069549A1 (en) * | 2021-10-20 | 2023-04-27 | Stealth Biotherapeutics Inc. | Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions |
| WO2023069255A1 (en) * | 2021-10-20 | 2023-04-27 | Stealth Biotherapeutics Inc. | Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions |
| US20230226105A1 (en) * | 2021-11-10 | 2023-07-20 | Reverspah Llc | Methods and compositions for treating cancer |
| CN114099678A (zh) * | 2021-11-23 | 2022-03-01 | 浙江大学 | 基于Keap1-Nrf2信号通路的晶状体损伤抑制剂 |
| KR102662922B1 (ko) * | 2022-05-31 | 2024-05-03 | 주식회사 세네릭스 | 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5602100A (en) | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
| ES2085865T3 (es) | 1988-06-30 | 1996-06-16 | Astra Ab | Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean. |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| DE69630918T2 (de) | 1995-06-09 | 2004-10-28 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Matrix für Iontophorese |
| US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| US5885958A (en) | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| AU1818299A (en) | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
| CA2329709A1 (en) | 1998-04-24 | 1999-11-04 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| SE9900961D0 (sv) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
| EP1218544B1 (en) | 1999-10-04 | 2009-06-03 | The University of Medicine and Dentistry of New Jersey | TAR RNA binding peptides |
| US6759520B1 (en) | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| US20050192215A1 (en) | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
| JP2001270832A (ja) * | 2000-03-27 | 2001-10-02 | Ito En Ltd | 網膜障害予防剤 |
| DE60143945D1 (de) | 2000-07-18 | 2011-03-10 | Cornell Res Foundation Inc | Medizinische verwendung von agonisten des mu-opioid rezeptors |
| US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| US20070015146A1 (en) | 2001-05-22 | 2007-01-18 | Gene Logic, Inc. | Molecular nephrotoxicology modeling |
| WO2004016214A2 (en) * | 2002-08-14 | 2004-02-26 | Medical College Of Georgia Research Institute, Inc. | Methods and compositions for treatment of macular and retinal disease |
| US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
| US20060172972A1 (en) | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| ES2540897T3 (es) | 2003-02-04 | 2015-07-14 | Cornell Research Foundation, Inc. | Usos de péptidos catiónicos aromáticos |
| JP2004323486A (ja) * | 2003-04-30 | 2004-11-18 | National Institute Of Advanced Industrial & Technology | 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬 |
| DK1625149T3 (en) | 2003-05-01 | 2016-05-30 | Cornell Res Foundation Inc | METHOD AND carrying complexes for delivery of molecules to cells |
| US7232824B2 (en) | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
| CN1938042B (zh) * | 2004-01-23 | 2010-06-02 | 科内尔研究基金会 | 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用 |
| SI1755616T1 (sl) | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| US20050272101A1 (en) | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| JP4760111B2 (ja) | 2005-04-26 | 2011-08-31 | 株式会社セガ | 映像オブジェクト表現用データ構造生成プログラム、映像オブジェクト表現用データ構造生成方法、映像ソフト開発装置、映像処理プログラム、映像処理方法、映像処理装置、映像オブジェクト表現用データ構造、および、記録媒体 |
| US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
| JP2007043629A (ja) * | 2005-06-30 | 2007-02-15 | Sony Corp | グラフィック・ユーザ・インタフェース装置と操作入力処理方法及び双方向コミュニケーション装置 |
| EP1904108B1 (en) | 2005-07-15 | 2011-11-30 | Chakshu Research, Inc. | Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin |
| EP3549594A1 (en) | 2005-09-16 | 2019-10-09 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
| WO2007043629A1 (ja) | 2005-10-05 | 2007-04-19 | Aqumen Biopharmaceuticals K.K. | エフリンｂ２を用いる血管新生の抑制方法 |
| US20070259377A1 (en) | 2005-10-11 | 2007-11-08 | Mickey Urdea | Diabetes-associated markers and methods of use thereof |
| TW200744627A (en) | 2006-02-21 | 2007-12-16 | Pfizer Prod Inc | Methods for the treatment of macular degeneration and related eye conditions |
| MX2008013211A (es) * | 2006-04-14 | 2008-10-22 | Novartis Ag | Uso de anticuerpos de il-1 para el tratamiento de trastornos oftalmicos. |
| US20080027082A1 (en) | 2006-06-19 | 2008-01-31 | Berthold Hocher | Use of adenosine a1 antagonists in radiocontrast media induced nephropathy |
| DE102006042329B4 (de) * | 2006-09-01 | 2008-08-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zum selektiven plasmachemischen Trockenätzen von auf Oberflächen von Silicium-Wafern ausgebildetem Phosphorsilikatglas |
| CN101600451A (zh) | 2006-12-11 | 2009-12-09 | 犹他大学研究基金会 | 用于治疗病理性血管生成和血管通透性的组合物和方法 |
| JP2008195655A (ja) * | 2007-02-14 | 2008-08-28 | Kitasato Institute | 糖尿病白内障の治療剤 |
| JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| RU2460526C2 (ru) * | 2007-05-25 | 2012-09-10 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна |
| CN101939019B (zh) * | 2008-02-07 | 2014-07-16 | 康奈尔大学 | 用于预防或治疗胰岛素抵抗性的方法 |
| CN107802821A (zh) | 2008-02-26 | 2018-03-16 | 康奈尔大学 | 用于防止和治疗急性肾损伤的方法 |
| JP2012521355A (ja) | 2009-03-20 | 2012-09-13 | ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル | 熱傷及び二次性合併症の予防及び治療方法 |
| FR2945540B1 (fr) | 2009-05-15 | 2012-06-08 | Rhodia Operations | Procede de preparation de mousse polyamide et mousse susceptible d'etre obtenue par ce procede |
| EP2464371B1 (en) | 2009-08-12 | 2016-03-16 | Cornell University | Methods for preventing or treating metabolic syndrome |
| EP3338788A1 (en) * | 2009-08-24 | 2018-06-27 | Stealth Peptides International, Inc. | Methods and copositions for preventing or treating opthalmic conditions |
| US20120329730A1 (en) * | 2010-01-25 | 2012-12-27 | Institut De Recherches Cliniques De Montreal | Aromatic-cationic peptides and uses of same |
| CA2790823A1 (en) * | 2010-02-26 | 2011-09-01 | University Of Florida Research Foundation, Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP3290433A1 (en) | 2010-05-03 | 2018-03-07 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| JP2014518213A (ja) | 2011-06-14 | 2014-07-28 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 芳香族カチオン性ペプチド及びその使用 |
| WO2014210056A1 (en) * | 2013-06-27 | 2014-12-31 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
| US20160199437A1 (en) * | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
| US20160228491A1 (en) * | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
-
2010
- 2010-08-23 EP EP17205537.8A patent/EP3338788A1/en not_active Withdrawn
- 2010-08-23 EP EP23194389.5A patent/EP4302829B1/en active Active
- 2010-08-23 WO PCT/US2010/046338 patent/WO2011025734A1/en active Application Filing
- 2010-08-23 JP JP2012526880A patent/JP6120399B2/ja active Active
- 2010-08-23 EP EP16186448.3A patent/EP3150215A1/en not_active Withdrawn
- 2010-08-23 SM SM20230433T patent/SMT202300433T1/it unknown
- 2010-08-23 EP EP18194243.4A patent/EP3485896A1/en not_active Withdrawn
- 2010-08-23 EP EP15177582.2A patent/EP2962695A1/en not_active Withdrawn
- 2010-08-23 EP EP15172384.8A patent/EP2990049A1/en not_active Withdrawn
- 2010-08-23 HU HUE20156769A patent/HUE064800T2/hu unknown
- 2010-08-23 PT PT201567690T patent/PT3708178T/pt unknown
- 2010-08-23 CN CN201510388677.1A patent/CN105056206A/zh active Pending
- 2010-08-23 HR HRP20231277TT patent/HRP20231277T1/hr unknown
- 2010-08-23 ES ES20156769T patent/ES2964555T3/es active Active
- 2010-08-23 LT LTEP20156769.0T patent/LT3708178T/lt unknown
- 2010-08-23 PL PL20156769.0T patent/PL3708178T3/pl unknown
- 2010-08-23 SI SI201032136T patent/SI3708178T1/sl unknown
- 2010-08-23 EP EP10812524.6A patent/EP2470191B1/en active Active
- 2010-08-23 PT PT108125246T patent/PT2470191E/pt unknown
- 2010-08-23 EP EP16175746.3A patent/EP3124036A1/en not_active Withdrawn
- 2010-08-23 EP EP14164726.3A patent/EP2813235A1/en not_active Withdrawn
- 2010-08-23 DK DK10812524.6T patent/DK2470191T3/da active
- 2010-08-23 EP EP18214554.0A patent/EP3524256A1/en not_active Withdrawn
- 2010-08-23 CN CN2010800481393A patent/CN102625709A/zh active Pending
- 2010-08-23 EP EP18205074.0A patent/EP3494983A1/en not_active Withdrawn
- 2010-08-23 EP EP15174180.8A patent/EP2957291A1/en not_active Withdrawn
- 2010-08-23 CN CN201610861402.XA patent/CN107412722A/zh active Pending
- 2010-08-23 EP EP16177723.0A patent/EP3175862A1/en not_active Withdrawn
- 2010-08-23 SI SI201030612T patent/SI2470191T1/sl unknown
- 2010-08-23 US US12/861,593 patent/US8470784B2/en active Active
- 2010-08-23 ES ES10812524.6T patent/ES2487633T3/es active Active
- 2010-08-23 FI FIEP20156769.0T patent/FI3708178T3/fi active
- 2010-08-23 CA CA2772094A patent/CA2772094C/en active Active
- 2010-08-23 EP EP17183644.8A patent/EP3292868A1/en not_active Withdrawn
- 2010-08-23 EP EP20156769.0A patent/EP3708178B1/en active Active
- 2010-08-23 EP EP14181858.3A patent/EP2826487A1/en not_active Withdrawn
- 2010-08-23 DK DK20156769.0T patent/DK3708178T3/da active
- 2010-08-23 PL PL10812524T patent/PL2470191T3/pl unknown
- 2010-08-23 EP EP17194835.9A patent/EP3318264A1/en not_active Withdrawn
-
2013
- 2013-05-17 US US13/897,070 patent/US9023807B2/en active Active
-
2015
- 2015-03-27 US US14/671,538 patent/US9549963B2/en active Active
- 2015-06-16 HK HK15105695.0A patent/HK1204958A1/en unknown
- 2015-07-20 HK HK16105839.6A patent/HK1217900A1/en unknown
- 2015-07-20 HK HK15106883.0A patent/HK1206258A1/en unknown
- 2015-10-02 JP JP2015197004A patent/JP6332757B2/ja active Active
-
2017
- 2017-01-09 US US15/401,527 patent/US10188692B2/en active Active
- 2017-05-29 JP JP2017105602A patent/JP6381737B2/ja active Active
-
2018
- 2018-06-01 HK HK18107246.7A patent/HK1247821A1/zh unknown
- 2018-07-31 JP JP2018143180A patent/JP2018162329A/ja active Pending
-
2019
- 2019-01-25 US US16/258,521 patent/US20200061147A1/en not_active Abandoned
-
2020
- 2020-06-02 JP JP2020096157A patent/JP7642965B2/ja active Active
- 2020-07-02 US US16/919,777 patent/US11612633B2/en active Active
-
2021
- 2021-10-18 JP JP2021170354A patent/JP2022001609A/ja active Pending
-
2023
- 2023-02-09 US US18/107,640 patent/US20230346874A1/en active Pending
- 2023-08-11 US US18/448,650 patent/US11944662B2/en active Active
- 2023-10-18 JP JP2023179375A patent/JP2023179733A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231277T1 (hr) | Peptid za upotrebu u prevenciji ili liječenju makularne degeneracije | |
| JP2013502460A5 (hr) | ||
| AR069729A1 (es) | Uso de sustancias para el tratamiento de la perdida de vision ocular en humanos con glaucoma y otras enfermedades oculares degenerativas | |
| ES2954412T3 (es) | Solución oftálmica | |
| AU2023226711A1 (en) | Compositions and methods for treating ophthalmic conditions | |
| JP6148664B2 (ja) | 眼科治療 | |
| JP2018521000A5 (hr) | ||
| CA2674080C (en) | Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof | |
| ES2810863T3 (es) | Yoduro de povidona, un conservante alternativo novelo para composiciones oftálmicas | |
| JP2009501726A (ja) | 眼科学的活性剤の製剤とその投与の方法 | |
| EP1904108A2 (en) | Formulation and method for administration of ophthalmologically active agents | |
| JP2019507758A5 (hr) | ||
| US9981041B2 (en) | Ophthalmic lubricating spray | |
| US20180289810A1 (en) | Sustained release eye drop formulations | |
| SI2036538T1 (sl) | Farmacevtsko stabilna spojina, ki jo sestavljajo timolol, dorzolamid in brimonidin | |
| HRP20192142T1 (hr) | Stabilni oftalmološki pripravak, posebno za liječenje sindroma suhog oka | |
| JP2024079810A (ja) | キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤 | |
| EP4275675A1 (en) | Drug delivery contact lens and ophthalmic pharmaceutical composition | |
| US20210361685A1 (en) | Tobramycin compound conjugates and derivative compositions | |
| CN111479567B (zh) | 包含FP激动剂和β-阻断剂的青光眼的治疗剂 | |
| Peridex | GINGIVITIS AND PERIODONTITIS | |
| OTC et al. | phenylephrine (C) | |
| Wroblewski et al. | Brinzolamide< Prop INN; USAN | |
| AU2013242820A1 (en) | Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof |